CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling
A peer-reviewed study published in Nature indicates that the protein CDCA5 promotes the progression of hepatocellular carcinoma by inhibiting ferroptosis. The research suggests CDCA5 could be a significant biomarker for prognosis and therapeutic intervention in liver cancer.
Why it matters
Identifying specific molecular pathways in cancer progression is critical for developing targeted therapies and improving patient outcomes in oncology.
Scientific Reports ( 2026 ) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in